In particular, a Sigma-2 receptor antagonist CT1812 has demonstrated a safety profile in the clinic [39] and is currently being tested as a treatment for Alzheimer’s disease in a Phase II trial (ClinicalTrials.gov: NCT03507790). This evidence concerns the gene TMEM97 and early-onset autosomal dominant Alzheimer disease.